On April 8, 2025 Edity Therapeutics Limited and Aurigene Oncology Limited (AOL), a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited, a clinical-stage biotechnology company, reported a strategic collaboration to create novel cell therapy medicines for difficult-to-treat solid tumors (Press release, Aurigene Discovery Technologies, APR 8, 2025, View Source [SID1234651829]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The partnership is bolstered by government grants awarded to both companies. Aurigene Oncology secured grant from the India-Israel Industrial R&D and Technology Innovation Fund, while Edity received non-dilutive financing from the Israel Innovation Authority. These grants will support the initial two years of joint research efforts. Both companies will work collaboratively to co-develop first joint program for solid tumors.

Edity’s proprietary delivery platform is addressing key challenges of cell therapies in solid tumors including, antigen heterogeneity, the immunosuppressive tumor microenvironment and tumor resistance to death. "We are thrilled to partner with Aurigene Oncology’s exceptional team, whose deep expertise in oncology development and cell therapy manufacturing is unparalleled," said Michal Golan Mashiach, CEO of Edity Therapeutics. "This collaboration is a pivotal step in advancing our mission to deliver transformative, curative medicines to cancer patients."